SMS Pharmaceuticals Limited (SMSPHARMA) fundamentals
SMS Pharmaceuticals Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as SMSPHARMA (ISIN INE812G01025). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What SMS Pharmaceuticals Limited does
SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic, and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel, lamotrigine, penciclovir, valaciclovir, and others. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.
Valuation and market data
| Last close | ₹463.45 |
|---|---|
| Market capitalisation | ₹3,828 crore |
| Enterprise value | ₹3,975 crore |
| P/E (TTM) | 0.00 |
| Price to book | 5.98 |
| Price to sales (TTM) | 4.22 |
| Book value per share | ₹77.44 |
| Dividend yield | 8.63% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Feb 28 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹895 crore | ₹117 crore | ₹88 crore | 0.00 |
| Mar 2025 | ₹789 crore | ₹92 crore | ₹67 crore | 8.16 |
| Mar 2024 | ₹714 crore | ₹66 crore | ₹49 crore | 5.89 |
| Mar 2023 | ₹527 crore | ₹5 crore | ₹4 crore | -0.83 |
| Mar 2022 | ₹525 crore | ₹69 crore | ₹68 crore | 7.35 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 68.1% |
|---|---|
| Foreign institutions (FII) | 0.7% |
| Mutual funds | 2.8% |
| Other domestic institutions | 0.0% |
| Retail and others | 28.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.